Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seribantumab Plus Fulvestrant in HRG+ Metastatic Breast Cancer
NCT03241810Phase 2Terminated
- Sponsor
- Elevation Oncology, Inc.
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Seribantumab + Fulvestrant with Placebo + Fulvestrant (2 arms). Primary endpoint: Progression Free Survival up to 13 months. Started Aug 2017; status: terminated.
02
Drugs
seribantumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03241810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241810.